Goh Sean L, Yap Kok H, Chua Kim C, Chao Victor T T
Royal Prince Alfred Hospital, Sydney, NSW, Australia
Department of Cardiothoracic Surgery, National Heart Centre, Singapore General Hospital, Singapore.
Interact Cardiovasc Thorac Surg. 2015 Mar;20(3):422-8. doi: 10.1093/icvts/ivu402. Epub 2014 Dec 4.
A best evidence topic was written according to a structured protocol. The question addressed was: does preoperative statin therapy prevent postoperative atrial fibrillation (AF) in patients undergoing cardiac surgery? There were 445 papers found using the reported search. From these, 12 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. This paper includes three systematic reviews with meta-analysis, five randomized controlled trials and four retrospective studies. All the papers compared either all or some of the following postoperative complications: mortality, morbidity, AF, length of hospital stay (intensive care unit and hospital) and inflammatory markers. The largest study in this paper includes a systematic review of 91 491 patients that showed a reduction in postoperative AF with preoperative statin therapy (OR = 0.71, 95% CI 0.61-0.82, P <0.0001). However, the durations (3 days to 2 months preoperatively), doses and types of preoperative statin differed between these papers. Although the majority of studies (10 of 12) support the use of statins preoperatively, 2 studies found no association between preoperative statin therapy and the reduction of postoperative AF. In conclusion, the available evidence suggests that preoperative statin therapy in patients undergoing elective cardiac surgery is associated with the following: (1) a lower incidence and risk of developing postoperative AF, (2) reduced stroke, (3) a shorter hospital stay and (4) reduced levels of inflammatory markers postoperatively. However, while the evidence supports the use of statins preoperatively, the optimal duration, dose and type of statin cannot be concluded from this review.
根据结构化方案撰写了一篇最佳证据主题。所探讨的问题是:术前他汀类药物治疗能否预防心脏手术患者术后房颤(AF)?通过报告的检索共找到445篇论文。其中,12篇代表了回答该临床问题的最佳证据。现将这些论文的作者、期刊、出版日期和国家、所研究的患者群体、研究类型、相关结局及结果制成表格。本文包括三项带有荟萃分析的系统评价、五项随机对照试验和四项回顾性研究。所有论文均比较了以下全部或部分术后并发症:死亡率、发病率、房颤、住院时间(重症监护病房和医院)以及炎症标志物。本文中规模最大的研究包括一项对91491例患者的系统评价,结果显示术前他汀类药物治疗可降低术后房颤发生率(OR = 0.71,95%CI 0.61 - 0.82,P <0.0001)。然而,这些论文中术前他汀类药物的使用时长(术前3天至2个月)、剂量和类型各不相同。尽管大多数研究(12篇中的10篇)支持术前使用他汀类药物,但有2项研究未发现术前他汀类药物治疗与降低术后房颤之间存在关联。总之,现有证据表明,择期心脏手术患者术前使用他汀类药物治疗与以下情况相关:(1)术后房颤的发生率和风险较低;(2)中风减少;(3)住院时间缩短;(4)术后炎症标志物水平降低。然而,虽然证据支持术前使用他汀类药物,但无法从本综述中得出他汀类药物的最佳使用时长、剂量和类型。